alirocumab
alirocumab: 5 clinical trials tracked.
alirocumab evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about alirocumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 2 study sponsors
Related indications
Clinical Trial Registry Records (5)
A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Weekly Alirocumab in Adults With Hypercholesterolemia
Primary endpoint: Percent change in LDL-C
Alirocumab and Cardiovascular Outcomes in Patients Without a Previous Myocardial Infarction or Stroke
Primary endpoint: Composite of Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or All-Cause Mortality
Reduction in Low-Density Lipoprotein Cholesterol With Alirocumab 150 mg as Compared With Inclisiran: Comparative Evaluation Via Target-Trial Emulation and G-Computation
Primary endpoint: Mean Percentage Reduction in Low Density Lipoprotein Cholesterol (LDL-C) From Baseline Over the 60 to 450 Days Follow-up
Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301
Primary endpoint: Evaluate the pathologic complete response (pCR) rate for neoadjuvant chemotherapy plus cemiplimab with alirocumab.
Impact of Alirocumab on Cardiovascular Events in Individuals With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
Primary endpoint: Composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or all-cause mortality